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SYSTEMATIC REVIEW AND META-ANALYSIS
Effects of Influenza Vaccine on Mortality 
and Cardiovascular Outcomes in Patients 
With Cardiovascular Disease: A Systematic 
Review and Meta- Analysis
Siva H. Yedlapati, MD, MPH*; Safi U. Khan , MD*; Swapna Talluri, MD; Ahmed N. Lone, MD; 
Muhammad Zia Khan, MD; Muhammad Shahzeb Khan , MD; Ann M. Navar , MD, PhD; 
Martha Gulati, MD, MS; Heather Johnson , MD; Seth Baum, MD; Erin D. Michos, MD, MHS
BACKGROUND: Influenza infection causes considerable morbidity and mortality in patients with cardiovascular disease. We as-
sessed the effects of the influenza vaccine on mortality and cardiovascular outcomes in patients with cardiovascular disease.
METHODS AND RESULTS: We searched PubMed, Embase, and the Cochrane Library through January 2020 for randomized con-
trolled trials and observational studies assessing the effects of influenza vaccine on mortality and cardiovascular outcomes 
in patients with cardiovascular disease. Estimates were reported as random effects risk ratios (RRs) with 95% CIs. Analyses 
were stratified by study design into randomized controlled trials and observational studies. A total of 16 studies (n=237 058), 
including 4 randomized controlled trials (n=1667) and 12 observational studies (n=235 391), were identified. Participants’ mean 
age was 69.2±7.01 years, 36.6% were women, 65.1% had hypertension, 31.1% had diabetes mellitus, and 23.4% were smok-
ers. At a median follow- up duration of 19.5 months, influenza vaccine was associated with a lower risk of all- cause mortality 
(RR, 0.75; 95% CI, 0.60– 0.93 [P=0.01]), cardiovascular mortality (RR, 0.82; 95% CI, 0.80– 0.84 [P<0.001]), and major adverse 
cardiovascular events (RR, 0.87; 95% CI, 0.80– 0.94 [P<0.001]) compared with control. The use of the influenza vaccine was 
not associated with a statistically significant reduction of myocardial infarction (RR, 0.73; 95% CI, 0.49– 1.09 [P=0.12]) com-
pared with control.
CONCLUSIONS: Data from both randomized controlled trials and observational studies support the use of the influenza vaccine 
in adults with cardiovascular disease to reduce mortality and cardiovascular events, as currently supported by clinical guide-
lines. Clinicians and health systems should continue to promote the influenza vaccine as part of comprehensive secondary 
prevention.
Key Words: cardiovascular disease ■ influenza vaccine ■ meta- analysis ■ mortality
The US Centers for Disease Control and Prevention (CDC) estimated ≈39 to 56  million influenza ill-nesses and 24 000 to 62 000 influenza- associated 
deaths during the year 2019 to 2020.1 Adults with car-
diovascular disease (CVD) are at notably higher risk 
of complications from influenza. Initial signals of the 
possible relationship between influenza and major ad-
verse cardiovascular events (MACE) were noticed in 
the early 1900s after the influenza pandemic in Europe 
and the United States when the incidence of myocar-
dial infarction (MI) and stroke peaked during the winter 
following respiratory infections.2 This interrelation was 
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later shown again in observational studies demonstrat-
ing a higher risk of cardiac events in patients with influ-
enza infection. In an observational study published in 
the New England Journal of Medicine in 2018, the au-
thors demonstrated a 6- fold increased risk of MI within 
7  days of confirmed influenza infection.3 Similarly, in 
a population- based study of adults hospitalized with 
influenza, almost 12% of patients had an acute cardio-
vascular event.4
The American Heart Association/American College 
of Cardiology Guideline for Secondary Prevention for 
Patients With Coronary and Other Atherosclerotic 
Vascular Disease: 2006 Update recommends influenza 
vaccination in all patients with established coronary ar-
tery disease (class I, Level of Evidence B),5 consistent 
with the CDC guidelines.6 Even with the available evi-
dence, influenza immunization rates remain low among 
individuals with CVD who reside in North America.7– 10 In 
a recent nationally representative sample of 19 793 pa-
tients with atherosclerotic CVD, 32.7% lacked influenza 
vaccination.11 Several reasons were identified, includ-
ing lack of systemic offering or awareness about the 
vaccine, lack of interest in vaccination, fears regarding 
the potential side effects of vaccination, and socioeco-
nomic disparities among young or elderly individuals or 
ethnic/racial minorities limiting access to usual care.9,11 
Another survey of board- certified cardiologists, en-
docrinologists, and pulmonologists found that cardi-
ologists were least likely to stock influenza vaccine.12 
Among practitioners who did not stock the vaccine, 
the most common reason cited was the assumption 
that patients would receive the vaccine elsewhere.
Multiple studies have shown the potential for reduc-
tion in MACE with the influenza vaccine.13– 15 However, 
the degree of risk reduction has varied among trials and 
observational studies.10,16– 21 Therefore, we performed 
a systematic review and meta- analysis aimed to inves-
tigate the effects of influenza vaccine on mortality and 
MACE in patients with CVD, stratified by study design.
METHODS
Data Availability Statement
The authors declare that all supporting data are avail-
able within the article (and its online supplementary 
files).
Data Sources and Searches
This meta- analysis was conducted in accord-
ance with the Cochrane Collaboration guidelines 
and was reported following PRISMA (Preferred 
Reporting Items for Systematic Reviews and Meta- 
Analyses).22,23 A comprehensive literature search 
was performed without language restriction using the 
electronic databases PubMed, Embase, Cochrane 
Library, and Clini calTr ials.gov through January 
2020. Additional online sources included web-
sites of major cardiovascular and medicine journals 
(https://www.nejm.org, https://www.thela ncet.com, 
https://www.thela ncet.com/, https://jaman etwork.
com, https://acade mic.oup.com/eurhe artj, www.
CLINICAL PERSPECTIVE
What Is New?
• In a meta- analysis of 4 randomized controlled 
trials and 12 observational studies, influenza 
vaccination was associated with 25% and 18% 
relative risk reduction in all- cause and cardio-
vascular mortality, respectively, in patients with 
cardiovascular disease.
• The mortality reduction was most likely driven 
in part by a 13% relative risk reduction in major 
adverse cardiovascular events.
What Are the Clinical Implications?
• In the context of nearly half of individuals lack-
ing routine influenza vaccination in the United 
States, this study reiterates the survival benefit 
and cardiovascular risk reduction achieved with 
the influenza vaccine in patients with cardiovas-
cular disease.
• These findings may help healthcare profession-
als and policymakers strongly advocate the in-
fluenza vaccination for secondary prevention of 
cardiovascular outcomes.
Nonstandard Abbreviations and Acronyms
CDC Centers for Disease Control and 
Prevention
FLUCAD Influenza Vaccination in Secondary 
Prevention From Coronary Ischemic 
Events in Coronary Artery Disease
FLUVACS Flu Vaccination in Acute Coronary 
Syndromes and Planned 
Percutaneous Coronary Interventions
IAMI Influenza Vaccination After 
Myocardial Infarction
INVESTED Influenza Vaccine to Effectively Stop 
Cardio Thoracic Events and 
Decompensated Heart Failure
IVCAD Efficacy of Influenza Vaccination in 
Reducing Cardiovascular Events in 
Patients With Coronary Artery 
Diseases
IVVE Influenza Vaccine in Patients With 
Heart Failure to Reduce Adverse 
Vascular Events
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onlin ejacc.org, http://annals.org/aim, and https://
www.ahajo urnals.org/journ al/circ); bibliographies 
of relevant studies; and meta- analyses. The search 
algorithm was: ((((((((("influenza vaccines"[MeSH 
Terms] OR ("influenza"[All Fields] AND "vaccines"[All 
Fields])) OR "influenza vaccines"[All Fields]) OR 
("influenza"[All Fields] AND "vaccine"[All Fields])) OR 
"influenza vaccine"[All Fields]) AND (((("cardiovascu-
lar diseases"[MeSH Terms] OR ("cardiovascular"[All 
Fields] AND "diseases"[All Fields])) OR "cardiovas-
cular diseases"[All Fields]) OR ("cardiovascular"[All 
Fields] AND "disease"[All Fields])) OR "cardiovascular 
disease"[All Fields])) OR ((("mortality"[MeSH Terms] 
OR "mortality"[All Fields]) OR "mortalities"[All Fields]) 
OR "mortality"[MeSH Subheading])) OR (("heart 
failure"[MeSH Terms] OR ("heart"[All Fields] AND 
"failure"[All Fields])) OR "heart failure"[All Fields])) OR 
(("heart failure"[MeSH Terms] OR ("heart"[All Fields] 
AND "failure"[All Fields])) OR "heart failure"[All Fields])) 
OR ((("stroke"[MeSH Terms] OR "stroke"[All Fields]) 
OR "strokes"[All Fields]) OR "stroke s"[All Fields])) 
OR (("myocardial infarction"[MeSH Terms] OR 
("myocardial"[All Fields] AND "infarction"[All Fields])) 
OR "myocardial infarction"[All Fields]).
Study Selection
The prespecified inclusion criteria were as follows: 
(1) RCTs or observational studies comparing the ef-
ficacy of influenza vaccine; (2) studies must have at 
least 50% of patients with established CVD (athero-
sclerotic CVD or heart failure [HF])24,25; (3) studies 
must report mortality and cardiovascular outcomes 
of interest; and (4) a follow- up duration of at least 
12 months assessing vaccine effectiveness for each 
influenza season. There were no restrictions on sam-
ple size or language.
After removing the duplicates and following the 
selection criteria, we screened the remaining articles 
at the title and abstract level and then at the full- text 
level. The process of study search and selection was 
performed independently by 2 investigators (S.T. and 
A.N.L.). Any conflicts were resolved by discussion, mu-
tual consensus, referring to the original study, and the 
third investigator’s opinion (S.U.K.).
Data Extraction, Outcomes, and Quality 
Assessment
Two investigators (S.T. and A.N.L.) independently ab-
stracted the data using prespecified data collection 
forms, appraised the abstractions’ accuracy, and re-
solved any discrepancies by consensus after discus-
sion with a third investigator (S.U.K.). The data were 
abstracted on the studies’ characteristics, crude point 
estimates, number of events, sample sizes, and follow-
 up duration. Two unblinded investigators (S.T. and 
A.N.L.) independently appraised the potential risks of 
bias of the trials using the Cochrane risk- of- bias tool 
and observational studies using the Newcastle- Ottawa 
scale at the study level (Figure S1 and Table S1, re-
spectively).26,27 The end points of interest were all- 
cause mortality, cardiovascular mortality, MACE, MI, 
and HF.
Data Synthesis and Analysis
Outcomes were pooled using a generic invariance 
random- effects model. The DerSimonian and Laird 
method was used for estimation of τ2.28 Analyses 
were stratified according to study design: RCTs 
and observational studies.26 For the meta- analysis, 
the threshold of at least 2 studies per study design 
was deemed compulsory. We reported effect sizes 
as risk ratios (RRs) with 95% CIs. We used I2 statis-
tics to measure the extent of unexplained statistical 
heterogeneity: I2>50% was considered a high de-
gree of between- study statistical heterogeneity. For 
subgroup analyses, we assumed a common among- 
study variance component among subgroups (pool 
within- group estimates of τ2).29 Publication bias was 
assessed using Egger regression test. Sensitivity 
analyses were performed by the exclusion of data re-
ported exclusively in abstracts because of the lack of 
confirmation in subsequent publication18 (Table S2). 
For all analyses, statistical significance was set at 
<5%. Comprehensive Meta- Analysis Version 3.0 
(Biostat Inc) was used.
RESULTS
Of 858 827 articles, 666 were assessed for eligibility 
after removing duplicates and screening at the title 
and abstract level; 650 articles were removed based 
on a priori study selection criteria. Ultimately, a total 
of 16 studies (n=237  058) encompassing 4 RCTs 
(n=1667) and 12 observational studies (n=235  391) 
were included (Figure 1). Participants’ mean age was 
69.2±7.01 years, 36.6% were women, 65.1% had hy-
pertension, 31.1% had diabetes mellitus, and 23.4% 
were smokers. The median follow- up duration was 
19.5 months (interquartile range, 12– 43.3 months). 
Baseline characteristics of studies are reported in the 
Table. Data were available on all end points; however, 
we refrained from reporting HF end points since only 1 
trial reported this outcome (Figure 2). Figure S2 dem-
onstrates the summary of the effect of the influenza 
vaccine on mortality and cardiovascular end points.
All- Cause Mortality
Four RCTs (n=1667) and 8 observational stud-
ies (n=164  047) reported all- cause mortality.7,10,16– 
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reduction in all- cause mortality compared with con-
trol (RR, 0.75; 95% CI, 0.60– 0.93 [P=0.01]) (I2=97%) 
(Figure  3). This benefit was consistent in RCTs (RR, 
0.53; 95% CI, 0.28– 0.99 [P=0.05]) and observational 
studies (RR, 0.79; 95% CI, 0.62– 0.99 [P=0.04]) (P for 
interaction=0.24).
Cardiovascular Mortality
Four RCTs (n=1667) and 3 observational studies 
(n=136 082) reported cardiovascular mortality.16– 19,34– 36 
Overall, influenza vaccine was associated with reduc-
tion in cardiovascular mortality compared with con-
trol (RR, 0.82; 95% CI, 0.80– 0.84 [P<0.001]) (I2=31%) 
(Figure  4). This benefit was consistent among study 
designs but more pronounced in RCTs (RR, 0.44; 
95% CI, 0.26– 0.76 [P<0.001]) than observational stud-
ies (RR, 0.82; 95% CI, 0.80– 0.84 [P<0.001]) (P for 
interaction=0.02).
Major Adverse Cardiovascular Events
Four RCTs (n=1667) and 3 observational studies 
(n=27  207) reported MACE.10,16– 21 Overall, influenza 
vaccine was associated with reduction in MACE 
compared with control (RR, 0.87; 95% CI, 0.80– 0.94 
[P<0.001]) (I2=51%) (Figure 5). While this benefit was 
consistent among study designs, reduction in RR 
was more pronounced in RCTs (RR, 0.57; 95% CI, 
0.43– 0.74 [P<0.001]) than observational studies (RR, 
0.90; 95% CI, 0.83– 0.98 [P=0.02]) (P for interaction 
<0.01).
Myocardial Infarction
Four RCTs (n=1667) and 3 observational studies 
(n=70  688) reported MI.16– 19,21,36,37 Overall, influenza 
vaccine was not significantly associated with reduc-
tion in MI compared with control (RR, 0.73; 95% CI, 
0.49– 1.09 [P=0.12]) (I2=64%) (Figure  6). This effect 
Figure 1. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta- Analyses) 
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was consistent among study designs: RCTs (RR, 
0.74; 95% CI, 0.38– 1.44 [P=0.38]) and observational 
studies (RR, 0.73; 95% CI, 0.44– 1.19 [P=0.20]) (P for 
interaction=0.95).
Sensitivity analyses by excluding abstract data18 
did not influence mortality and MACE end points. 
Egger regression test did not detect small study bias 
(P=0.63).
DISCUSSION
In this meta- analysis of 237 058 patients with CVD, in-
fluenza vaccination was associated with a significant 
reduction in all- cause mortality, cardiovascular mortal-
ity, and MACE. While a numerical reduction in MI was 
associated with the influenza vaccine, statistical signifi-
cance was not achieved. The effects of the influenza 
vaccine were consistent among RCTs and observa-
tional studies. The influence of influenza vaccine on HF 
was not reported in the main results because of the 
paucity of randomized data. However, the summary 
estimate was consistent with a 29% RR reduction in 
HF, predominantly driven by the 27% reduction noted 
from observational data.
There have been multiple postulated mechanisms 
that could explain an increased cardiovascular risk after 
influenza infection, including atherosclerotic plaque de-
stabilization and subsequent thrombosis, deposition of 
immune complexes in atherosclerotic plaques, and ele-
vation of macrophage circulation into the arteries result-
ing in coronary vascular events.38– 40 Proinflammatory 
cytokine release, endothelial dysfunction, sympathetic 
activation, and exaggerated fluid shifts leading to vol-
ume overload are few mechanisms explaining acute HF 
development.41– 44 Our meta- analysis provides further 
confirmation that preventing influenza infection through 
vaccination can reduce MACE and mortality risk. 
Despite lack of statistically significant reduction for MI, 
the directionality of the effect estimates with numerical 
27% RR reduction appears to influence MACE, which 
consequently resulted in the observed survival bene-
fit with influenza vaccine.10,18,19,21 However, since these 
findings do not represent causative effect, these obser-
vations should be considered hypothesis- generating.
We compared our results with other meta- 
analyses.13– 15 Loomba et al14 analyzed 3 RCTs and 2 
observational studies including 292 383 patients and 
showed a reduction in all- cause mortality (odds ratio 
[OR], 0.61 [95% CI, 0.57– 0.64]), MI (OR, 0.73 [95% CI, 
0.57– 0.93]), and MACE (OR, 0.47 [95% CI, 0.29– 0.74]) 
in patients who received influenza vaccination. This 
study was a mixed cohort of patients with and with-
out CVD and did not comment on whether mortality 
benefit was persistent in secondary CVD prevention. 
Moreover, the influence of study design on summary 
estimates was not examined. Udell et al15 analyzed 
6 RCTs comprising only 36.2% of patients with CVD 
and showed a reduction in composite cardiovascular 
events with influenza vaccination versus control (2.9% 
versus 4.7%; RR, 0.64 [95% CI, 0.48– 0.86]). However, 
the influenza vaccine was not shown to reduce car-
diovascular mortality (RR, 0.81 [95% CI, 0.36– 1.83]). 
The most likely explanation of the difference in mor-
tality estimate between their study and ours was 
Figure 2. Effect of influenza vaccine on mortality and cardiovascular end points.
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the limited mean follow- up duration (7.9  months) of 
studies included in Udell et al. Whereas, we included 
studies with a follow- up duration of at least 12 months 
to demonstrate significant differences between rare 
events, such as mortality.45 This is important given 
that differences in rare events between interventions, 
such as mortality, take a longer follow- up duration to 
emerge. Clar et al13 performed a meta- analysis of 8 
RCTs encompassing patients with and without CVD. 
In 4 RCTs focused on the secondary prevention of 
Figure 4. Effect of influenza vaccine on cardiovascular mortality.
Studies included Jackson et al,36 Kaya et al,35 Modin et al,34 FLUVACS (Flu Vaccination in Acute Coronary Syndromes 
and Planned Percutaneous Coronary Interventions),17 FLUCAD (Influenza Vaccination in Secondary Prevention From 
Coronary Ischemic Events in Coronary Artery Disease),16 IVCAD (Efficacy of Influenza Vaccination in Reducing 
Cardiovascular Events in Patients With Coronary Artery Diseases),18 and Phrommintikul et al.19 RCT indicates 
randomized control trial.
Figure 3. Effect of influenza vaccine on all- cause mortality.
Studies included Wu et al,20 Vardeny et al,10 de Diego et al,7 Liu et al,30 Kopel et al,32 Wu et al,31 Blaya- Nováková et 
al,33 Modin et al,34 FLUVACS (Flu Vaccination in Acute Coronary Syndromes and Planned Percutaneous Coronary 
Interventions),17 FLUCAD (Influenza Vaccination in Secondary Prevention From Coronary Ischemic Events in Coronary 
Artery Disease),16 IVCAD (Efficacy of Influenza Vaccination in Reducing Cardiovascular Events in Patients With Coronary 
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cardiovascular outcomes, cardiovascular mortality 
was reduced by influenza vaccination (RR, 0.45; 95% 
CI, 0.26– 0.76). However, this study differed from our 
meta- analysis by excluding observational data. In our 
unique meta- analysis, we attempted to generate con-
sensus regarding persistent cardiovascular benefits 
between “real- world data” and RCTs regarding the 
efficacy of the influenza vaccine in CVD.
Figure 6. Effect of influenza vaccine on myocardial infarction.
Studies included Jackson et al,36 Mohseni et al,37 Lavallee et al,21 FLUVACS (Flu Vaccination in Acute Coronary Syndromes and 
Planned Percutaneous Coronary Interventions),17 FLUCAD (Influenza Vaccination in Secondary Prevention From Coronary Ischemic 
Events in Coronary Artery Disease),16 IVCAD (Efficacy of Influenza Vaccination in Reducing Cardiovascular Events in Patients With 
Coronary Artery Diseases),18 and Phrommintikul et al.19 RCT indicates randomized control trial.
Figure 5. Effect of influenza vaccine on major adverse cardiovascular events.
Studies included Wu et al,20 Lavallee et al,21 Vardeny et al,10 FLUVACS (Flu Vaccination in Acute Coronary Syndromes and Planned 
Percutaneous Coronary Interventions),17 FLUCAD (Influenza Vaccination in Secondary Prevention From Coronary Ischemic Events in 
Coronary Artery Disease),16 IVCAD (Efficacy of Influenza Vaccination in Reducing Cardiovascular Events in Patients With Coronary 
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Influenza vaccination was associated with a 25% 
reduced risk of all- cause death comparable in size ef-
fect to guideline- directed therapy with β- blockers and 
angiotensin- converting enzyme inhibitors with reduc-
tions in mortality of ≈20% to 25%, respectively.34,46– 48 
This is a substantial reduction in mortality given the 
safety, feasibility, and cost- efficiency of influenza vac-
cination, and thus should be considered alongside 
other cardiovascular prevention therapies. In the re-
cent INVESTED (Influenza Vaccine to Effectively Stop 
Cardio Thoracic Events and Decompensated Heart 
Failure) trial, high- dose vaccine showed comparable 
outcomes compared with a standard vaccine in high- 
risk patients with CVD.49 Two other ongoing RCTs,50,51 
the IAMI (Influenza Vaccination After Myocardial 
Infarction) trial that randomized patients with acute cor-
onary syndrome undergoing coronary angiography to 
the influenza vaccine versus placebo,50 and the IVVE 
(Influenza Vaccine in Patients With Heart Failure to 
Reduce Adverse Vascular Events) trial that compared a 
composite cardiovascular end point in patients with HF 
who received the influenza vaccine compared with pla-
cebo,51 might further aid in strengthening the evidence 
in favor of efficacy profile of the influenza vaccine in 
specific patients with CVD.
Our analysis was limited by inherent shortcom-
ings of study- level meta- analysis, such as study de-
sign, baseline variables of population, definition of end 
points, and heterogenous follow- up durations. While 
we included studies of only patients with prevalent 
CVD, there were limited and inconsistent data reported 
in the studies regarding specific underlying CVD sub-
types (coronary artery disease, peripheral artery dis-
ease, cerebrovascular disease, or HF); we were unable 
to further stratify by these subgroups. Event rates were 
low, compromising the power of specific end points 
such as MI. Similarly, scarcity of data on other hard 
end points, such as stroke, did not allow us to explore 
the influence of relevant cardiovascular end points on 
mortality and MACE. Some studies carried higher rela-
tive weight in pooled estimates than other studies. For 
instance, FLUVACS (Flu Vaccination in Acute Coronary 
Syndromes and Planned Percutaneous Coronary 
Interventions)17 contributed >50% relative weight and 
can influence the end points. That said, the direc-
tionality of the majority of component studies of this 
meta- analysis favored the influenza vaccine for survival 
improvement.
CONCLUSIONS
The influenza vaccine was associated with a lower risk 
of total and cardiovascular mortality in patients with 
CVD. Influenza is the most common respiratory infec-
tion.52 Yet, only 45% of adults in the United States were 
vaccinated against influenza during the 2018 to 2019 
season despite the available evidence favoring survival 
benefit in CVD.53 Influenza vaccination in patients with 
or at risk for CVD is a standard of care, and all provid-
ers should assume the responsibility of inquiring about 
vaccination status, providing education, and ensuring 
that patients have the opportunity to be vaccinated. 
The current study may help care clinicians and health 
policymakers to strongly advocate the influenza vac-
cination for secondary prevention of cardiovascular 
outcomes.
ARTICLE INFORMATION
Received October 8, 2020; accepted January 14, 2021.
Affiliations
From the Department of Medicine, Erie County Medical Center, Buffalo, NY 
(S.H.Y., A.N.L., M.Z.K.); Department of Medicine, West Virginia University, 
Morgantown, WV (S.U.K.); Department of Medicine, Guthrie Health System/
Robert Packer Hospital, Sayre, PA (S.T.); Department of Medicine, John 
H Stroger Jr. Hospital of Cook County, Chicago, IL (M.S.K.); Division of 
Cardiology, UT Southwestern Medical Center, Dallas, TX (A.M.N.); Division of 
Cardiology, University of Arizona, Phoenix, AZ (M.G.); Boca Raton Regional 
Hospital/Baptist Health of South Florida, Boca Raton, FL (H.J.); Excel 
Medical Clinical Trials, Boca Raton, FL (S.B.); and The Ciccarone Center 
for the Prevention of Cardiovascular Disease, Johns Hopkins School of 
Medicine, Baltimore, MD (E.D.M.).
Sources of Funding
Dr Michos is supported by the Blumenthal Scholars Award in Preventive 
Cardiology at Johns Hopkins University.
Disclosures
Dr Navar has received funding for research to her institution from Amarin, 
Amgen, Janssen, Regeneron, and Sanofi; and honoraria and consulting fees 
from Amarin, Amgen, AstraZeneca, BI, Cerner, 89Bio, Esperion, Janssen, 
Lilly, New Amsterdam, Novartis, NovoNordisk, Pfizer, Regeneron, Sanofi, 






 1. Centers for Disease Control and Prevention. US flu season: preliminary 
burden estimates. 2019– 2020. Available at: https://www.cdc.gov/flu/
about/ burde n/2019- 2020.html. Accessed January 9, 2021.
 2. Collins SD. Excess mortality from causes other than influenza and pneu-
monia during influenza epidemics. Public Health Rep. 1932;47:2159– 
2179. DOI: 10.2307/4580606.
 3. Kwong JC, Schwartz KL, Campitelli MA, Chung H, Crowcroft NS, 
Karnauchow T, Katz K, Ko DT, McGeer AJ, McNally D, et al. Acute myo-
cardial infarction after laboratory- confirmed influenza infection. N Engl J 
Med. 2018;378:345– 353. DOI: 10.1056/NEJMo a1702090.
 4. Chow EJ, Rolfes MA, O’Halloran A, Anderson EJ, Bennett NM, Billing 
L, Chai S, Dufort E, Herlihy R, Kim S, et al. Acute cardiovascular events 
associated with influenza in hospitalized adults: a cross- sectional study. 
Ann Intern Med. 2020;173:605– 613. DOI: 10.7326/M20- 1509.
 5. Smith SC, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, Grundy 
SM, Hiratzka L, Jones D, Krumholz HM, et al. AHA/ACC guidelines for 
secondary prevention for patients with coronary and other atheroscle-
rotic vascular disease: 2006 update. Circulation. 2006;113:2363– 2372. 
DOI: 10.1161/CIRCU LATIO NAHA.106.174516.
 6. Grohskopf LA, Alyanak E, Broder KR, Walter EB, Fry AM, Jernigan DB. 
Prevention and control of seasonal influenza with vaccines: recommen-




 http://ahajournals.org by on A
pril 2, 2021
J Am Heart Assoc. 2021;10:e019636. DOI: 10.1161/JAHA.120.019636 10
Yedlapati et al Influenza Vaccine and Cardiovascular Outcomes
States, 2019– 20 influenza season. MMWR Recomm Rep. 2019;68:1– 
21. DOI: 10.15585/ mmwr.rr6803a1.
 7. de Diego C, Vila- Corcoles A, Ochoa O, Rodriguez- Blanco T, Salsench 
E, Hospital I, Bejarano F, del Puy Muniain M, Fortin M, Canals M, et 
al. Effects of annual influenza vaccination on winter mortality in elderly 
people with chronic heart disease. Eur Heart J. 2009;30:209– 216. DOI: 
10.1093/eurhe artj/ehn498.
 8. Kadoglou NPE, Bracke F, Simmers T, Tsiodras S, Parissis J. Influenza 
infection and heart failure- vaccination may change heart failure 
prognosis? Heart Fail Rev. 2017;22:329– 336. DOI: 10.1007/s1074 
1- 017- 9614- 7.
 9. Singleton JA, Wortley P, Lu PJ. Influenza vaccination of persons 
with cardiovascular disease in the United States. Tex Heart Inst J. 
2004;31:22– 27.
 10. Vardeny O, Claggett B, Udell JA, Packer M, Zile M, Rouleau J, Swedberg 
K, Desai AS, Lefkowitz M, Shi V, et al. Influenza vaccination in patients 
with chronic heart failure: the PARADIGM- HF trial. JACC Heart Fail. 
2016;4:152– 158. DOI: 10.1016/j.jchf.2015.10.012.
 11. Grandhi GR, Mszar R, Vahidy F, Valero- Elizondo J, Blankstein R, Blaha 
MJ, Virani SS, Andrieni JD, Omer SB, Nasir K. Sociodemographic dis-
parities in influenza vaccination among adults with atherosclerotic car-
diovascular disease in the United States. JAMA Cardiol. 2021;6:87– 91. 
DOI: 10.1001/jamac ardio.2020.3978.
 12. Davis MM, Wortley PM, Ndiaye SM, Cowan AE, Osta AD, Clark SJ. 
Influenza vaccine for high- risk non- elderly adults: a national sur-
vey of subspecialists. Hum Vaccin. 2008;4:229– 233. DOI: 10.4161/
hv.4.3.5516.
 13. Clar C, Oseni Z, Flowers N, Keshtkar- Jahromi M, Rees K. Influenza vac-
cines for preventing cardiovascular disease. Cochrane Database Syst 
Rev. 2015;5:CD005050. DOI: 10.1002/14651 858.CD005 050.pub3.
 14. Loomba RS, Aggarwal S, Shah PH, Arora RR. Influenza vaccination and 
cardiovascular morbidity and mortality: analysis of 292,383 patients. 
J Cardiovasc Pharmacol Ther. 2012;17:277– 283. DOI: 10.1177/10742 
48411 429965.
 15. Udell JA, Zawi R, Bhatt DL, Keshtkar- Jahromi M, Gaughran F, 
Phrommintikul A, Ciszewski A, Vakili H, Hoffman EB, Farkouh ME, et 
al. Association between influenza vaccination and cardiovascular out-
comes in high- risk patients: a meta- analysis. JAMA. 2013;310:1711– 
1720. DOI: 10.1001/jama.2013.279206.
 16. Ciszewski A, Bilinska ZT, Brydak LB, Kepka C, Kruk M, Romanowska 
M, Ksiezycka E, Przyluski J, Piotrowski W, Maczynska R, et al. Influenza 
vaccination in secondary prevention from coronary ischaemic events 
in coronary artery disease: FLUCAD study. Eur Heart J. 2008;29:1350– 
1358. DOI: 10.1093/eurhe artj/ehm581.
 17. Gurfinkel EP, Leon de la Fuente R, Mendiz O, Mautner B. Flu vacci-
nation in acute coronary syndromes and planned percutaneous coro-
nary interventions (FLUVACS) Study. Eur Heart J. 2004;25:25– 31. DOI: 
10.1016/j.ehj.2003.10.018.
 18. Keshtkar- Jahromi M, Vakili H, Rahnavardi MT. The efficacy of in-
fluenza vaccination in reducing cardiovascular events in patients 
with coronary artery diseases: IVCAD study. Clin Microbiol Infect. 
2009;15:S395– S396.
 19. Phrommintikul A, Kuanprasert S, Wongcharoen W, Kanjanavanit R, 
Chaiwarith R, Sukonthasarn A. Influenza vaccination reduces cardio-
vascular events in patients with acute coronary syndrome. Eur Heart J. 
2011;32:1730– 1735. DOI: 10.1093/eurhe artj/ehr004.
 20. Wu HH, Chang YY, Kuo SC, Chen YT. Influenza vaccination and 
secondary prevention of cardiovascular disease among Taiwanese 
elders- a propensity score- matched follow- up study. PLoS One. 
2019;14:e0219172. DOI: 10.1371/journ al.pone.0219172.
 21. Lavallee PC, Labreuche J, Fox KM, Lavados P, Mattle H, Steg PG, 
Amarenco P; PERFORM, OPTIC, and AMISTAD Investigators A. 
Influenza vaccination and cardiovascular risk in patients with recent TIA 
and stroke. Neurology. 2014;82:1905– 1913. DOI: 10.1212/WNL.00000 
00000 000456.
 22. van Tulder M, Furlan A, Bombardier C, Bouter L; Editorial Board of the 
Cochrane Collaboration Back Review Group. Updated method guide-
lines for systematic reviews in the Cochrane Collaboration Back Review 
Group. Spine. 2003;28:1290– 1299. DOI: 10.1097/01.BRS.00000 
65484.95996.AF.
 23. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred 
reporting items for systematic reviews and meta- analyses: the 
PRISMA statement. Ann Intern Med. 2009;151:264– 269. DOI: 
10.7326/0003- 4819- 151- 4- 20090 8180- 00135.
 24. Khan SU, Khan MU, Valavoor S, Khan MS, Okunrintemi V, Mamas MA, 
Leucker TM, Blaha MJ, Michos ED. Association of lowering apolipopro-
tein B with cardiovascular outcomes across various lipid- lowering ther-
apies: systematic review and meta- analysis of trials. Eur J Prev Cardiol. 
2020;27:1255– 1268. DOI: 10.1177/20474 87319 871733.
 25. Koskinas KC, Siontis GCM, Piccolo R, Mavridis D, Räber L, Mach F, 
Windecker S. Effect of statins and non- statin LDL- lowering medications 
on cardiovascular outcomes in secondary prevention: a meta- analysis 
of randomized trials. Eur Heart J. 2018;39:1172– 1180. DOI: 10.1093/
eurhe artj/ehx566.
 26. Khan SU, Khan MU, Ghani AR, Lone AN, Arshad A, Kaluski E. Meta- 
analysis of antithrombotic therapy in atrial fibrillation after percutane-
ous coronary intervention. Am J Cardiol. 2018;121:1200– 1206. DOI: 
10.1016/j.amjca rd.2018.01.036.
 27. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman 
AD, Savović J, Schulz KF, Weeks L, Sterne JA. The Cochrane 
Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 
2011;343:d5928. DOI: 10.1136/bmj.d5928.
 28. DerSimonian R, Laird N. Meta- analysis in clinical trials. Control Clin 
Trials. 1986;7:177– 188. DOI: 10.1016/0197- 2456(86)90046 - 2.
 29. Borenstein M, Higgins JP. Meta- analysis and subgroups. Prev Sci. 
2013;14:134– 143. DOI: 10.1007/s1112 1- 013- 0377- 7.
 30. Liu IF, Huang CC, Chan WL, Huang PH, Chung CM, Lin SJ, Chen JW, 
Leu HB. Effects of annual influenza vaccination on mortality and hospi-
talization in elderly patients with ischemic heart disease: a nationwide 
population- based study. Prev Med. 2012;54:431– 433. DOI: 10.1016/j.
ypmed.2012.03.020.
 31. Wu WC, Jiang L, Friedmann PD, Trivedi A. Association between pro-
cess quality measures for heart failure and mortality among US veter-
ans. Am Heart J. 2014;168:713– 720. DOI: 10.1016/j.ahj.2014.06.024.
 32. Kopel E, Klempfner R, Goldenberg I. Influenza vaccine and survival in 
acute heart failure. Eur J Heart Fail. 2014;16:264– 270. DOI: 10.1002/
ejhf.14.
 33. Blaya- Nováková V, Prado- Galbarro FJ, Sarria- Santamera A. Effects of 
annual influenza vaccination on mortality in patients with heart failure. 
Eur J Public Health. 2016;26:890– 892. DOI: 10.1093/eurpu b/ckw141.
 34. Modin D, Jorgensen ME, Gislason G, Jensen JS, Kober L, Claggett 
B, Hegde SM, Solomon SD, Torp- Pedersen C, Biering- Sorensen T. 
Influenza vaccine in heart failure. Circulation. 2019;139:575– 586. DOI: 
10.1161/CIRCU LATIO NAHA.118.036788.
 35. Kaya H, Beton O, Acar G, Temizhan A, Cavusoğlu Y, Guray U, Zoghi 
M, Ural D, Ekmekci A, Gungor H, et al. Influence of influenza vacci-
nation on recurrent hospitalization in patients with heart failure. Herz. 
2017;42:307– 315. DOI: 10.1007/s0005 9- 016- 4460- 2.
 36. Jackson LA, Yu O, Heckbert SR, Psaty BM, Malais D, Barlow WE, 
Thompson WW; Vaccine Safety Datalink Study Group. Influenza vacci-
nation is not associated with a reduction in the risk of recurrent coronary 
events. Am J Epidemiol. 2002;156:634– 640. DOI: 10.1093/aje/kwf073.
 37. Mohseni H, Kiran A, Khorshidi R, Rahimi K. Influenza vaccination and risk 
of hospitalization in patients with heart failure: a self- controlled case series 
study. Eur Heart J. 2017;38:326– 333. DOI: 10.1093/eurhe artj/ehw411.
 38. Conti CR. Vascular events responsible for thrombotic occlusion of a blood 
vessel. Clin Cardiol. 1993;16:761– 762. DOI: 10.1002/clc.49601 61103.
 39. Hebsur S, Vakil E, Oetgen WJ, Kumar PN, Lazarous DF. Influenza and 
coronary artery disease: exploring a clinical association with myocardial 
infarction and analyzing the utility of vaccination in prevention of myo-
cardial infarction. Rev Cardiovasc Med. 2014;15:168– 175.
 40. Kinlay S, Ganz P. Role of endothelial dysfunction in coronary artery dis-
ease and implications for therapy. Am J Cardiol. 1997;80:11I– 16I. DOI: 
10.1016/S0002 - 9149(97)00793 - 5.
 41. Tomiyama H, Yamashina A. Vascular dysfunction: a key player in 
chronic cardio- renal syndrome. Intern Med. 2015;54:1465– 1472. DOI: 
10.2169/inter nalme dicine.54.4502.
 42. Marti CN, Georgiopoulou VV, Kalogeropoulos AP. Acute heart fail-
ure: patient characteristics and pathophysiology. Curr Heart Fail Rep. 
2013;10:427– 433. DOI: 10.1007/s1189 7- 013- 0151- y.
 43. Davies MJ. The composition of coronary- artery plaques. N Engl J Med. 
1997;336:1312– 1314. DOI: 10.1056/NEJM1 99705 01336 1809.
 44. Chan NN, Colhoun HM, Vallance P. Cardiovascular risk factors as de-
terminants of endothelium- dependent and endothelium- independent 
vascular reactivity in the general population. J Am Coll Cardiol. 
2001;38:1814– 1820. DOI: 10.1016/S0735 - 1097(01)01669 - 2.
 45. Khan SU, Rahman H, Talluri S, Kaluski E. The clinical benefits and 




 http://ahajournals.org by on A
pril 2, 2021
J Am Heart Assoc. 2021;10:e019636. DOI: 10.1161/JAHA.120.019636 11
Yedlapati et al Influenza Vaccine and Cardiovascular Outcomes
atrial fibrillation: a systematic review and meta- analysis. JACC Clin 
Electrophysiol. 2018;4:626– 635. DOI: 10.1016/j.jacep.2018.03.003.
 46. Flather MD, Yusuf S, Kober L, Pfeffer M, Hall A, Murray G, Torp- 
Pedersen C, Ball S, Pogue J, Moye L, et al. Long- term ACE- inhibitor 
therapy in patients with heart failure or left- ventricular dysfunction: a 
systematic overview of data from individual patients. ACE- Inhibitor 
Myocardial Infarction Collaborative Group. Lancet. 2000;355:1575– 
1581. DOI: 10.1016/S0140 - 6736(00)02212 - 1.
 47. McAlister FA, Wiebe N, Ezekowitz JA, Leung AA, Armstrong PW. 
Meta- analysis: beta- blocker dose, heart rate reduction, and death in 
patients with heart failure. Ann Intern Med. 2009;150:784– 794. DOI: 
10.7326/0003- 4819- 150- 11- 20090 6020- 00006.
 48. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, 
Drazner MH, Filippatos GS, Fonarow GC, Givertz MM, et al. 2017 
ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guide-
line for the management of heart failure: a report of the American 
College of Cardiology/American Heart Association Task Force on 
Clinical Practice Guidelines and the Heart Failure Society of America. 
Circulation. 2017;136:e137– e161. DOI: 10.1161/CIR.00000 00000 
000509.
 49. Vardeny O, Kim K, Udell JA, Joseph J, Desai AS, Farkouh ME, Hegde 
SM, Hernandez AF, McGeer A, Talbot HK, et al. Effect of high- dose 
trivalent vs standard- dose quadrivalent influenza vaccine on mortality 
or cardiopulmonary hospitalization in patients with high- risk cardiovas-
cular disease: a randomized clinical trial. JAMA. 2021;325:39– 49. DOI: 
10.1001/jama.2020.23649.
 50. Frobert O, Gotberg M, Angeras O, Jonasson L, Erlinge D, Engstrom T, 
Persson J, Jensen SE, Omerovic E, James SK, et al. Design and ratio-
nale for the Influenza vaccination After Myocardial Infarction (IAMI) trial. 
A registry- based randomized clinical trial. Am Heart J. 2017;189:94– 
102. DOI: 10.1016/j.ahj.2017.04.003.
 51. Loeb M, Dokainish H, Dans A, Palileo- Villanueva LM, Roy A, Karaye K, 
Zhu J, Liang Y, Goma F, Damasceno A, et al. Randomized controlled 
trial of influenza vaccine in patients with heart failure to reduce adverse 
vascular events (IVVE): rationale and design. Am Heart J. 2019;212:36– 
44. DOI: 10.1016/j.ahj.2019.02.009.
 52. Warren- Gash C, Smeeth L, Hayward AC. Influenza as a trigger for acute 
myocardial infarction or death from cardiovascular disease: a system-
atic review. Lancet Infect Dis. 2009;9:601– 610. DOI: 10.1016/S1473 
- 3099(09)70233 - 6.
 53. Chung JR, Rolfes MA, Flannery B, Prasad P, O’Halloran A, Garg S, Fry 
AM, Singleton JA, Patel M, Reed C, et al. Effects of influenza vaccination 
in the United States during the 2018– 2019 influenza season. Clin Infect 








Table S1. Newcastle-Ottawa scale for quality assessment and bias assessment of observational studies.  

















follow up of 
cohort 
 
De Diego et al.7  1 1 1 1 1 1 1 0 6/8 
Liu et al.30 1 1 1 1 0 1 1 1 7/8 
Wu et al.20 1 1 1 1 0 1 1 0 6/8 
Kopel et al.31 1 1 1 1 1 1 1 0 7/8 
Blaya-Novakova et al.34 1 1 1 1 0 1 1 0 6/8 
Vardeny et al.10 1 1 1 1 0 0 1 1 6/8 
Modin et al.33 1 1 1 1 1 0 1 1 7/8 
Wu et al.32 1 1 1 1 0 1 1 0 6/8 
Kaya et al.36 1 1 1 1 1 0 1 1 7/8 
Jackson et al.35 1 1 1 1 0 1 1 0 6/8 
Lavallee et al.21 1 1 1 1 0 1 1 0 6/8 
Mohseni et al.37  1 1 1 1 1 0 1 1 7/8 
 






















Table S2. Sensitivity analysis by removal of IVCAD trial. 
Outcome RR [95% Confidence Interval] 
All-cause mortality 0.48 [0.25, 0.94]  
Cardiovascular mortality 0.40 [0.23, 0.71] 
MACE 0.56 [0.42, 0.73] 
Myocardial infarction 0.64 [0.32, 1.31] 
 










Figure S1. Cochrane quality assessment tool for assessment of risk of bias for the randomized controlled trials. 
 
FLUVACS, Flu vaccination in acute coronary syndromes and planned percutaneous coronary interventions study; FLUCAD, Influenza vaccination in secondary 
prevention from coronary ischemic events in coronary artery disease study; IVCAD, The efficacy of influenza vaccination in reducing cardiovascular events in 
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